Kura Oncology Inc (NASDAQ:KURA) – Equities researchers at Piper Jaffray Companies lifted their FY2019 earnings estimates for Kura Oncology in a report released on Tuesday, November 5th. Piper Jaffray Companies analyst T. Van. Buren now expects that the company will post earnings per share of ($1.55) for the year, up from their previous forecast of ($1.75). Piper Jaffray Companies also issued estimates for Kura Oncology’s Q4 2019 earnings at ($0.44) EPS, Q1 2021 earnings at ($0.55) EPS, Q2 2021 earnings at ($0.60) EPS, Q3 2021 earnings at ($0.55) EPS and FY2021 earnings at ($2.20) EPS.
A number of other research firms also recently issued reports on KURA. ValuEngine downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Zacks Investment Research downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub upgraded shares of Kura Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, October 18th. Wedbush restated a “positive” rating on shares of Kura Oncology in a research report on Wednesday, September 4th. Finally, JMP Securities restated a “market outperform” rating and set a $22.00 target price on shares of Kura Oncology in a research report on Thursday, September 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $26.22.
NASDAQ KURA opened at $15.53 on Friday. The company has a market capitalization of $672.35 million, a PE ratio of -9.03 and a beta of 2.57. The company has a fifty day moving average of $14.92 and a 200 day moving average of $16.88. Kura Oncology has a 1 year low of $11.01 and a 1 year high of $21.42. The company has a debt-to-equity ratio of 0.03, a current ratio of 23.50 and a quick ratio of 23.50.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Brown Advisory Inc. purchased a new position in Kura Oncology in the second quarter valued at $11,799,000. Vanguard Group Inc. increased its holdings in Kura Oncology by 23.0% in the second quarter. Vanguard Group Inc. now owns 2,012,548 shares of the company’s stock valued at $39,628,000 after buying an additional 376,172 shares in the last quarter. Marshall Wace LLP increased its holdings in Kura Oncology by 1,449.5% in the second quarter. Marshall Wace LLP now owns 347,698 shares of the company’s stock valued at $6,846,000 after buying an additional 325,258 shares in the last quarter. Citadel Advisors LLC purchased a new position in Kura Oncology in the second quarter valued at $5,940,000. Finally, Monashee Investment Management LLC purchased a new position in Kura Oncology in the second quarter valued at $4,646,000. 84.97% of the stock is owned by institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.